Literature DB >> 8881908

Immunisation policies--successes, failures and the future.

E Miller1.   

Abstract

Mesh：

Substances：

Year:  1996        PMID： 8881908      PMCID： PMC500601          DOI： 10.1136/jcp.49.8.620

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN： 0021-9746            Impact factor:   3.411


× No keyword cloud information.
  12 in total

1.  Update--the United States measles epidemic, 1989-1990.

Authors:  J S Gindler; W L Atkinson; L E Markowitz
Journal:  Epidemiol Rev       Date:  1992       Impact factor: 6.222

2.  MEASLES IMMUNIZATION WITH KILLED VIRUS VACCINE. SERUM ANTIBODY TITERS AND EXPERIENCE WITH EXPOSURE TO MEASLES EPIDEMIC.

Authors:  L W RAUH; R SCHMIDT
Journal:  Am J Dis Child       Date:  1965-03

Review 3.  Vaccine technologies: view to the future.

Authors:  N R Rabinovich; P McInnes; D L Klein; B F Hall
Journal:  Science       Date:  1994-09-02       Impact factor: 47.728

4.  Interpretation of serological surveillance data for measles using mathematical models: implications for vaccine strategy.

Authors:  N J Gay; L M Hesketh; P Morgan-Capner; E Miller
Journal:  Epidemiol Infect       Date:  1995-08       Impact factor: 2.451

5.  Invasive Haemophilus influenzae disease: the impact of Hib immunisation.

Authors:  M P Slack
Journal:  J Med Microbiol       Date:  1995-02       Impact factor: 2.472

Review 6.  Potential of polymer microencapsulation technology for vaccine innovation.

Authors:  W Morris; M C Steinhoff; P K Russell
Journal:  Vaccine       Date:  1994-01       Impact factor: 3.641

7.  Russian contribution to OPV.

Authors:  V I Agol; S G Drozdov
Journal:  Biologicals       Date:  1993-12       Impact factor: 1.856

8.  Oral poliovirus vaccine: history of its development and use and current challenge to eliminate poliomyelitis from the world.

Authors:  A B Sabin
Journal:  J Infect Dis       Date:  1985-03       Impact factor: 5.226

9.  Use of adjuvant containing mycobacterial cell-wall skeleton, monophosphoryl lipid A, and squalane in malaria circumsporozoite protein vaccine.

Authors:  L S Rickman; D M Gordon; R Wistar; U Krzych; M Gross; M R Hollingdale; J E Egan; J D Chulay; S L Hoffman
Journal:  Lancet       Date:  1991-04-27       Impact factor: 79.321

10.  Long-term survival after Edmonston-Zagreb measles vaccination in Guinea-Bissau: increased female mortality rate.

Authors:  P Aaby; K Knudsen; H Whittle; I M Lisse; J Thaarup; A Poulsen; M Sodemann; M Jakobsen; L Brink; U Gansted
Journal:  J Pediatr       Date:  1993-06       Impact factor: 4.406
View more
  1 in total

Review 1.  Nanotechnology in vaccine delivery.

Authors:  Laura J Peek; C Russell Middaugh; Cory Berkland
Journal:  Adv Drug Deliv Rev       Date:  2008-02-07       Impact factor: 15.470
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.